Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16499846 | 0.74 | APLNR (0.32) | APLNR | |
| SCHEMBL18709642 | 0.72 | APLNR (0.33) | APLNR | |
| SCHEMBL9991970 | 0.72 | TSHR (0.39) | APLNR | |
| SCHEMBL26556218 | 0.72 | APLNR (0.31) | APLNR | |
| Hydrochloric Acid SCHEMBL28145155 | 0.70 | TSHR (0.37) | APLNR | |
| SCHEMBL1933922 | 0.70 | TSHR (0.37) | APLNR | |
| SCHEMBL28036740 | 0.70 | — | — | |
| SCHEMBL23183520 | 0.69 | APLNR (0.33) | APLNR | |
| SCHEMBL26869804 | 0.69 | — | — | |
| SCHEMBL19115012 | 0.67 | JAK2 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109711-A1 | MACROCYCLIC SULFONAMIDE MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4680607-A1 | BICYCLIC UREAS AS KINASE INHIBITORS | Incyte Corporation (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20240317744-A1 | Bicyclic Ureas As Kinase Inhibitors | INCYTE CORPORATION | 2024-09-26 | — | — | US | disclosed |
| WO-2024191996-A1 | BICYCLIC UREAS AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2024-09-19 | — | — | WO | disclosed |
| US-20230339886-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-10-26 | — | — | US | disclosed |
| WO-2023122093-A1 | REV-ERB AGONISTS FOR TH17-MEDIATED INFLAMMATORY DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2022258023-A1 | COMPOUND AS CDK KINASE INHIBITOR AND USE THEREOF | 郑州同源康医药有限公司 | 2022-12-15 | — | — | WO | disclosed |
| EP-3950692-A1 | NOVEL TRICYCLIC COMPOUNDS | AbbVie Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3950692-A1 | NOVEL TRICYCLIC COMPOUNDS | AbbVie Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| WO-2021263278-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-12-30 | — | — | WO | disclosed |
| US-20130216497-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBOTT LABORATORIES | 2013-08-22 | — | — | US | disclosed |
| US-20130216497-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBOTT LABORATORIES | 2013-08-22 | — | — | US | disclosed |
| US-8426411-B2 | Tricyclic compounds | ABBOTT LABORATORIES (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426411-B2 | Tricyclic compounds | ABBOTT LABORATORIES (US) | 2013-04-23 | — | — | US | disclosed |
| EP-2506716-A1 | NOVEL TRICYCLIC COMPOUNDS | Abbott Laboratories (US) | 2012-10-10 | — | — | EP | disclosed |
| US-20110311474-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110311474-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110311474-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2011-12-22 | — | — | US | disclosed |
| WO-2011068881-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011068881-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109711-A1 | MACROCYCLIC SULFONAMIDE MODULATORS | HCRTR2, HCRTR1, CNR1 | APLNR 313/4885 |
| US-20230339886-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | NR1H2, NR1H3, NR1D1 | APLNR 1095/4885 |
| US-20240317744-A1 | Bicyclic Ureas As Kinase Inhibitors | JAK2, UCK2, ULK2 | APLNR 2899/4885 |
| US-20110311474-A1 | Novel Tricyclic Compounds | CYP11B2, CYP11B1, ABCB1 | APLNR 3026/4885 |
| US-20130216497-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | APLNR 3026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.